Joint Bookrunner on Perspective Therapeutics’ $175.0 Million Underwritten Registered Direct

Oppenheimer & Co. Inc. acted as Joint Bookrunner on Perspective Therapeutics’ $175.0 Million Underwritten Registered Direct

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced the pricing of its underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $175.0 million, before deducting underwriting discounts and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective. The financing included participation from Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital (a Citadel company), Affinity Asset Advisors, HBM Healthcare Investments, Ally Bridge Group and other leading healthcare specialist and long-only investors.

Perspective intends to use the net proceeds it will receive from the offering to advance the clinical development of product candidates, continue to invest in the Company’s manufacturing facilities, and for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although Perspective has no present commitments or agreements to do so.

Healthcare Life Sciences Investment Banking